Radiation exposure after 177Lu-DOTATATE and 177Lu-PSMA-617 therapy

Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors

Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text

Medicine, Oncology, Pharmacology +17

OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.

Michael G. Stabin, Richard Sparks, Eric A. Crowe · PubMed · 2005 · 1.4K citations

Medicine, Internal Medicine, Nuclear Medicine +14

Release of patients after therapy with unsealed radionuclides

Annals of the ICRP · 2004 · 154 citations

Medicine, Nuclear Medicine, Radiation Protection +16

Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)

Makoto Hosono, Hideharu Ikebuchi, Yoshihide Nakamura et al. · Annals of Nuclear Medicine · 2018 · 64 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors

Phillipe J. Calais, J. Harvey Turner · Annals of Nuclear Medicine · 2014 · 59 citations

Medicine, Nuclear Medicine, Oncology +16